gptkbp:instance_of
|
gptkb:biotechnology
|
gptkbp:acquisition
|
gptkb:Celgene_Corporation
|
gptkbp:awards
|
Best Places to Work
Innovative Company Award
Top 100 Biotech Companies
|
gptkbp:ceo
|
gptkb:Andrew_Obenshain
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Australia
gptkb:Canada
gptkb:Japan
gptkb:United_States
gptkb:Lenti_Globin
gptkb:Skysona
gptkb:Zynteglo
Phase 2
Phase 3
Phase 1/2
|
gptkbp:collaboration
|
gptkb:Harvard_University
gptkb:University_of_Pennsylvania
gptkb:Children's_Hospital_of_Philadelphia
|
gptkbp:financials
|
publicly traded
market cap over $1 billion
revenue from gene therapies
|
gptkbp:focus
|
gptkb:gene_therapy
|
gptkbp:focus_area
|
gptkb:Oncology
rare diseases
severe genetic diseases
|
gptkbp:focuses_on
|
gptkb:gene_therapy
|
gptkbp:founded
|
gptkb:2010
|
gptkbp:founded_in
|
gptkb:1992
|
gptkbp:founder
|
gptkb:Nick_Leschly
|
gptkbp:funding
|
gptkb:venture_capital
|
gptkbp:has_part
|
gptkb:film_production_company
research and development
clinical trials
business development
regulatory affairs
commercial operations
|
gptkbp:has_product
|
gptkb:Skysona
gptkb:Zynteglo
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bluebird Bio
|
gptkbp:investment
|
$1.5 billion
|
gptkbp:mission
|
transform lives through gene therapy
|
gptkbp:number_of_employees
|
200-500
|
gptkbp:partnership
|
gptkb:GSK
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:Novartis
|
gptkbp:product
|
Lenti Globin for beta-thalassemia
Skysona for cerebral adrenoleukodystrophy
Zynteglo for beta-thalassemia
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:European_Medicines_Agency
|
gptkbp:research_focus
|
genetic disorders
oncology
immunology
|
gptkbp:stock_symbol
|
BLUE
|
gptkbp:technology
|
Lentiviral vector
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
gptkbp:vision
|
a world where genetic diseases are treated effectively.
|
gptkbp:website
|
bluebirdbio.com
|
gptkbp:bfsParent
|
gptkb:BLU-701
gptkb:Bayer_AG
|
gptkbp:bfsLayer
|
5
|